- S&P 500 7,659.44 −1.09%
- Dow Jones 52,002.41 −0.34%
- Nasdaq 26,713.03 +0.08%
- VIX 19.99 +21.45%
- 10-year Treasury 5.09% −0.01
- Dollar index 121.40 −0.14%
- WTI crude $101.91 +1.04%
Biotech calendar: October 2027
Industry-sponsored phase 2 and phase 3 trials with an estimated primary completion in October 2027, from ClinicalTrials.gov.
Trial readouts
130 trials: 44 phase 3 (including phase 2/3) and 86 phase 2. Phase 3 first, then by date. Click a column to sort; type to filter.
| Primary completion | Sponsor | Drug | Condition | Phase | Status | Record |
|---|---|---|---|---|---|---|
| Oct 2027 | AFT Pharmaceuticals, Ltd. | Combogesic® tablets, Acetaminophen 500mgA Study of Combogesic® 325 in Adolescent Patients With Moderate to Severe Postoperative Pain Associated With Orthopedic Surgery | Post Operative Pain, Acute | Phase 3 | Not yet recruiting | NCT07225140 |
| Oct 2027 | Acacia Pharma Ltd | RemimazolamInvestigation of Remimazolam in Children Undergoing Sedation for Medical Procedures | Pediatric ALL | Phase 2/3 | Active not recruiting | NCT04851717 |
| Oct 2027 | BeOne Medicines Ltd. | Zanubrutinib, TacrolimusA Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy | Primary Membranous Nephropathy | Phase 2/3 | Active not recruiting | NCT05707377 |
| Oct 2027 | Jiangsu Hengrui Medicine | SHR-1918A Trial to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia | Hyperlipidemia | Phase 3 | Recruiting | NCT07230730 |
| Oct 2027 | Bukwang Pharmaceutical | Lurasidone, Background Antidepressant TherapyStudy of Lurasidone as Adjunctive Treatment in Patients With Major Depressive Disorder With Inadequate Response to Antidepressant Monotherap… | Major Depressive Disorder (MDD), Major Depressive Disorder With Psychotic Features | Phase 3 | Not yet recruiting | NCT07781293 |
| Oct 2027 | Carnot Laboratories | Bofanglutide, SemaglutideBALANCE-DM2 Study of Bofanglutide in Adults With Type 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Phase 3 | Not yet recruiting | NCT07628985 |
| Oct 2027 | Chengdu New Radiomedicine Technology Co. LTD. | NRT6003 Injection, cTACEChinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere | Unresectable Hepatocellular Carcinoma | Phase 3 | Active not recruiting | NCT06900543 |
| Oct 2027 | Jiangsu Hengrui Medicine | HRS-5965A Trial of HRS-5965 Capsule in Primary IgA Nephropathy | Primary IgA Nephropathy | Phase 3 | Recruiting | NCT07014826 |
| Oct 2027 | Chiesi Farmaceutici S.p.A. | PRX-102 1 mg/kg every 2 weeks, PRX-102 2 mg/kg every 4 weeksStudy to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease | Fabry Disease | Phase 2/3 | Recruiting | NCT05710692 |
| Oct 2027 | Eli Lilly and Company | TirzepatideA Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2) | Obesity, Weight Gain | Phase 3 | Recruiting | NCT06439277 |
| Oct 2027 | Eli Lilly and Company | Imlunestrant, Tamoxifen, Anastrozole and 2 moreA Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer | Breast Neoplasms | Phase 3 | Active not recruiting | NCT05514054 |
| Oct 2027 | Eli Lilly and Company | TirzepatideA Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | Obesity, Overweight | Phase 3 | Active not recruiting | NCT05556512 |
| Oct 2027 | EyePoint Pharmaceuticals | EYP-1901, Aflibercept (2.0 mg)COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME | Diabetic Macular Edema, DME and 1 more | Phase 3 | Active not recruiting | NCT07449936 |
| Oct 2027 | EyePoint Pharmaceuticals | EYP-1901, Aflibercept (2.0 mg)CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME | Diabetic Macular Edema, DME and 1 more | Phase 3 | Active not recruiting | NCT07449923 |
| Oct 2027 | Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd. | Rupatifen Fumarate Capsules, Rupatadine Fumarate TabletsRupatifen Fumarate Capsules in Patients With Seasonal Allergic Rhinitis | Seasonal Allergic Rhinitis | Phase 3 | Recruiting | NCT07711262 |
| Oct 2027 | Harmony Biosciences Management, Inc. | HBS-301 tabletA Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH) | Idiopathic Hypersomnia | Phase 3 | Recruiting | NCT07500090 |
| Oct 2027 | Harmony Biosciences Management, Inc. | HBS-301A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Narcolepsy | EDS, Cataplexy and 2 more | Phase 3 | Recruiting | NCT07675135 |
| Oct 2027 | J-Pharma Co., Ltd. | Nanvuranlat, Physician's Best ChoiceA Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choic… | Advanced Biliary Tract Cancer, Biliary Tract Cancer (BTC) | Phase 3 | Recruiting | NCT07265674 |
| Oct 2027 | Kallyope Inc. | ElismetrepA Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine | Migraine | Phase 3 | Recruiting | NCT07816367 |
| Oct 2027 | Loxo Oncology, Inc. | Pirtobrutinib, IbrutinibA Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL… | Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic and 2 more | Phase 3 | Recruiting | NCT05254743 |
| Oct 2027 | Neurocrine Biosciences | NBI-1117568NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia | Schizophrenia | Phase 3 | Recruiting | NCT06963034 |
| Oct 2027 | Argenx SE | efgartigimod PH20 SCA Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia | Primary Immune Thrombocytopenia | Phase 3 | Active not recruiting | NCT04812925 |
| Oct 1, 2027 | Daiichi Sankyo | Trastuzumab DeruxtecanTrastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastati… | Breast Cancer | Phase 3 | Recruiting | NCT05950945 |
| Oct 1, 2027 | Roche Holding | Glofitamab, Polatuzumab vedotin, Rituximab and 3 moreAn Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CH… | Large B-Cell Lymphoma | Phase 3 | Active not recruiting | NCT06047080 |
| Oct 1, 2027 | MicroPort NeuroTech Co., Ltd. | Experimental Device A, a self-expanding rapamycin target-e…, Experimental Device B, a balloon-expandable rapamycin targ…, Apollo® Intracranial Artery Stent System, a balloon-expand…A Randomized Trial of the Rapamycin Target Eluting Stent for the Treatment of Symptomatic Cerebral Artery Atherosclerotic Disease（TARGET-DRE… | Intracranial Arteriosclerosis | Phase 3 | Not yet recruiting | NCT06925971 |
| Oct 1, 2027 | Pfizer | ibuzatrelvirA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are … | COVID-19 SARS-CoV-2 Infection | Phase 3 | Recruiting | NCT06679140 |
| Oct 1, 2027 | Zhejiang Vimgreen Pharmaceuticals, Ltd. | VG081821ACVG081821AC Tablets for Early to Mid-stage Parkinson's Disease | Parkinson Disease (PD) | Phase 2/3 | Recruiting | NCT07725562 |
| Oct 2, 2027 | Boehringer Ingelheim | TenecteplaseA Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen W… | Acute Ischemic Stroke | Phase 3 | Recruiting | NCT07361302 |
| Oct 4, 2027 | AstraZeneca | Budesonide/Albuterol metered dose inhaler, MDI, Albuterol sulfate metered dose inhaler, MDIA Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma | Asthma | Phase 3 | Recruiting | NCT06471257 |
| Oct 5, 2027 | UCB | rozanolixizumabAn Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis | Generalized Myasthenia Gravis | Phase 3 | Active not recruiting | NCT06540144 |
| Oct 7, 2027 | Qilu Pharmaceutical Co., Ltd. | QLC7401QLC7401 Monotherapy in Non-familial Hypercholesterolemia or Mixed Dyslipidemia | Primary Hypercholesterolemia or Mixed Hyperlipidemia | Phase 3 | Not yet recruiting | NCT07444086 |
| Oct 7, 2027 | Argenx SE | Empasiprubart IVA Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP | Chronic Inflammatory Demyelinating Polyneuropathy, CIDP and 1 more | Phase 3 | Recruiting | NCT07091630 |
| Oct 12, 2027 | Pfizer | PF-08653944A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | Obesity, Overweight and/or Obesity and 3 more | Phase 3 | Active not recruiting | NCT07400653 |
| Oct 13, 2027 | AstraZeneca | BDA MDI, AS MDIEvaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma | Asthma | Phase 3 | Recruiting | NCT06307665 |
| Oct 15, 2027 | AstraZeneca | Puxitatug Samrotecan, Doxorubicin, PaclitaxelPuxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) | Endometrial Cancer, Malignant Solid Tumour | Phase 3 | Recruiting | NCT07044336 |
| Oct 15, 2027 | Servier Affaires Médicales | Ivosidenib 500mg Oral Tablet, AzacitidineAn Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukem… | Acute Myeloid Leukemia (AML) | Phase 3 | Recruiting | NCT05907057 |
| Oct 15, 2027 | Transdermal Delivery Solutions Corp | Human Insulin, Finger-actuated, Metered Pump SprayerDose Response Study of Transdermal Human Insulin in Patients | Glucose, High Blood | Phase 2/3 | Not yet recruiting | NCT05159453 |
| Oct 16, 2027 | Immunocore | Brenetafusp, Nivolumab, Nivolumab + RelatlimabIMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) | Advanced Melanoma | Phase 3 | Recruiting | NCT06112314 |
| Oct 17, 2027 | Suzhou Abogen Biosciences Co., Ltd. | ABO1108Phase III Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or Above | Varicella-zoster Virus | Phase 3 | Recruiting | NCT07817108 |
| Oct 18, 2027 | Merck & Co. | MK-8527, Emtricitabine/tenofovir disoproxil (FTC/TDF)A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010) | Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis | Phase 3 | Recruiting | NCT07071623 |
| Oct 18, 2027 | Novartis | IptacopanLong-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria | Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Active not recruiting | NCT04747613 |
| Oct 20, 2027 | Phathom Pharmaceuticals, Inc. | VonoprazanA Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Sy… | Symptomatic Non-erosive Gastroesophageal Reflux Disease | Phase 3 | Recruiting | NCT07752407 |
| Oct 20, 2027 | Suzhou Kintor Pharmaceutical Inc, | KX-826 0.5% BID, KX-826 1.0% BIDTo Evaluate Efficacy and Safety of TopicalKX-826 Solution in Chinese Male Patients With Androgenetic Alopecia | Androgenetic Alopecia (AGA) | Phase 2/3 | Not yet recruiting | NCT06622824 |
| Oct 20, 2027 | Throne Biotechnologies Inc. | Stem Cell Educator therapyClinical Application of Stem Cell Educator Therapy in Type 1 Diabetes | Type 1 Diabetes | Phase 3 | Recruiting | NCT04011020 |
| Oct 2027 | AFT Pharmaceuticals, Ltd. | Rapamycin cream, Pulsed dyed laserRapamycin Dose-Ranging Efficacy Study in Port Wine Stains | Port Wine Stains | Phase 2 | Not yet recruiting | NCT07436611 |
| Oct 2027 | Akeso | AK112 low dose, Chemotherapy, Olaparib and 1 moreCombination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer | Platinum-sensitive Ovarian Cancer | Phase 2 | Recruiting | NCT06686030 |
| Oct 2027 | BrYet US, Inc. | ML-016ML-016 in Advanced Cancer With Lung and/or Liver Involvement | Advanced Solid Tumor With Lung and/or Liver Involvement | Phase 1/2 | Recruiting | NCT07723482 |
| Oct 2027 | Climb Bio, Inc. | budoprutugA Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy | Primary Membranous Nephropathy | Phase 2 | Recruiting | NCT07096843 |
| Oct 2027 | Daré Bioscience, Inc. | Lopinavir / ritonavirA Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV) | Human Papilloma Virus (HPV), High-risk Human Papillomavirus Infection | Phase 2 | Recruiting | NCT07601074 |
| Oct 2027 | Dendrogenix | DX243First Clinical Study to Evaluate Safety, Tolerability & PK of DX243 in Healthy Volunteers and Patients With Hearing Loss | Age-related Hearing Loss | Phase 2 | Recruiting | NCT07637981 |
| Oct 2027 | Endevica Bio | TCMCB07Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Aden… | Cancer Weight Loss | Phase 2 | Recruiting | NCT06937177 |
| Oct 2027 | Enzychem Lifesciences Corporation | EC-18Determine the Dose-dependent Efficacy and Safety of EC-18 in Patients With Moderate to Severe Atopic Dermatitis | Atopic Dermatitis | Phase 2 | Not yet recruiting | NCT06487000 |
| Oct 2027 | Evommune, Inc. | EVO756, Dose 1, EVO756, Dose 2Study of EVO756 in Adults With Migraine | Migraine | Phase 2 | Recruiting | NCT07616128 |
| Oct 2027 | Forward Therapeutics | FT2109 Dosing Regimen 1, FT2109 Dosing Regimen 2Phase 2 Trial of FT2109 for the Treatment of Psoriatic Arthritis | Psoriatic Arthritis (PsA) | Phase 2 | Not yet recruiting | NCT07869134 |
| Oct 2027 | Frontier Medicines Corporation | FMC-376A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors | Advanced Solid Tumors With KRAS G12C Mutations, Solid Tumor, Adult and 4 more | Phase 1/2 | Recruiting | NCT06244771 |
| Oct 2027 | Hanmi Pharmaceutical | HM15275Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus, T2DM | Phase 2 | Recruiting | NCT07527650 |
| Oct 2027 | Helixon Biotechnology (Suzhou) Co., Ltd | HXN6005Study of HXN6005 in Healthy Participants and Patients With Moderate-to-Severe Atopic Dermatitis | Health Adult Subjects, Atopic Dermatitis (AD) | Phase 1/2 | Not yet recruiting | NCT07782476 |
| Oct 2027 | Helsinn Healthcare SA | IV NEPA (fosnetupitant/palonosetron), Reference Treatment: IV ondansetron infusion, Reference Treatment: IV fosaprepitant infusionStudy With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients… | Nausea and Vomiting Chemotherapy-Induced, Nausea Post Chemotherapy | Phase 2 | Recruiting | NCT06904235 |
| Oct 2027 | ImmunoGenesis | Evofosfamide, Zalifrelimab, BalstilimabA Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab | Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma and 1 more | Phase 1/2 | Recruiting | NCT06782555 |
| Oct 2027 | Jemincare | JYB1904Trial of JYB1904 Injection in Patients With Perennial Allergic Rhinitis | Perennial Allergic Rhinitis | Phase 2 | Not yet recruiting | NCT07459452 |
| Oct 2027 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | JSKN033, Platinum, BevacizumabJSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer | Cervical Cancer | Phase 2 | Not yet recruiting | NCT07497074 |
| Oct 2027 | Jiangsu Hengrui Medicine | HRS-4508+ Capecitabine, HRS-4508+ Trastuzumab, HRS-4508+ Trastuzumab+ Pertuzumab and 6 moreA Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor | Solid Tumor | Phase 1/2 | Recruiting | NCT07140393 |
| Oct 2027 | Kumquat Biosciences Inc. | KQB198, Imatinib (Gleevec)KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line) | GIST - Gastrointestinal Stromal Tumor, GIST and 3 more | Phase 2 | Recruiting | NCT07406633 |
| Oct 2027 | Locate Bio Ltd | LDGraftA Study of LDGraft In Single Level Lumbar Interbody Fusion | Degenerative Disc Disease Lumbar | Phase 1/2 | Recruiting | NCT07858643 |
| Oct 2027 | Menarini Group | Meropenem plus vaborbactamA Study to Assess How Vaborem® is Taking up in the Body and Tolerated in Paediatric Patients With Gram Negative Infections, Including But No… | Gram Negative Infections | Phase 2 | Recruiting | NCT06828848 |
| Oct 2027 | Mirum Pharmaceuticals | Low dose of MRM-3379, Middle Dose of MRM-3379, High dose of MRM-3379 and 1 moreStudy of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM) | Fragile X Syndrome | Phase 2 | Recruiting | NCT07209462 |
| Oct 2027 | Monte Rosa Therapeutics | Oral MRT-2359, ApalutamideStudy of Oral MRT-2359 With Apalutamide in Prostate Cancer | Castration-Resistant Prostate Cancer (CRPC), Castration-Resistant Prostate Cancer and 2 more | Phase 2 | Recruiting | NCT07745361 |
| Oct 2027 | NC Medial Research Inc | NCS-01A Study of NCS-01 in Patients With Acute Ischemic Stroke | Ischemic Stroke | Phase 1/2 | Active not recruiting | NCT03915431 |
| Oct 2027 | Neurothera Labs Inc. | SCI-110SCI-110 in the Treatment of Tourette Syndrome | Tourette Syndrome | Phase 2 | Not yet recruiting | NCT05126888 |
| Oct 2027 | NovelMed Therapeutics | NM8074Study of NM8074 in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV) | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Phase 2 | Not yet recruiting | NCT06226662 |
| Oct 2027 | Opko Health Inc. | CTAP101Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants | CKD Stage 3, CKD Stage 4 and 2 more | Phase 2 | Recruiting | NCT07494045 |
| Oct 2027 | Oruka Therapeutics, Inc. | ORKA-002Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis | Plaque Psoriasis | Phase 2 | Active not recruiting | NCT07474792 |
| Oct 2027 | Palisade Bio, INC. | PALI-2108A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis | Ulcerative Colitis (UC), Severe Ulcerative Colitis and 1 more | Phase 2 | Recruiting | NCT07845487 |
| Oct 2027 | Perceive Biotherapeutics, Inc. | VOY-101Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration | Age-Related Macular Degeneration, Geographic Atrophy and 2 more | Phase 1/2 | Active not recruiting | NCT06087458 |
| Oct 2027 | Pharmacosmos A/S | SP-420A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia or Low-risk Myelodysplastic Syndromes | Beta Thalassemia Major Anemia, Myelodysplastic Syndrome | Phase 2 | Recruiting | NCT05693909 |
| Oct 2027 | Pharming Technologies B.V. | KL1333Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease | Primary Mitochondrial Disease | Phase 2 | Recruiting | NCT05650229 |
| Oct 2027 | Qilu Pharmaceutical Co., Ltd. | QLH12016, abiraterone acetate, enzalutamideStudy of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate Cancer | Prostatic Neoplasms | Phase 1/2 | Not yet recruiting | NCT07104110 |
| Oct 2027 | SMSbiotech | Stem cellsA Study to Investigate Small Mobile Stem Cells (SMS) in Moderate to Severe Chronic Obstructive Pulmonary Disease | Chronic Obstructive Lung Disease | Phase 1/2 | Not yet recruiting | NCT07871890 |
| Oct 2027 | SNIPR Biome Aps. | SNIPR001 consists of genetically modified bacteriophages s…Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 i… | E Coli Infections, Allogenic Transplant Patients | Phase 1/2 | Recruiting | NCT06938867 |
| Oct 2027 | Serum Institute of India Pvt. Ltd. | Hexavalent (DTwP-HepB-rPV-Hib) Vaccine, HEXASIILSafety and Immunogenicity of a Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Recombinant Poliomyelitis and Haemophilus In… | Diptheria Immunization, Tetanus Immunization and 4 more | Phase 1/2 | Not yet recruiting | NCT07855172 |
| Oct 2027 | Jiangsu Hengrui Medicine | HRS-4642;Adebrelimab Injection; nab-paclitaxel; gemcitabine, HRS-4642;nab-paclitaxel; gemcitabineHRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors | Locally Advanced or Metastatic Pancreatic Cancer With | Phase 1/2 | Recruiting | NCT07296341 |
| Oct 2027 | Shanghai Zhongze Therapeutics Co., Ltd. | SIPI6398 TabletsA Positron Emission Tomography (PET) Study to Evaluate Dopamine D2 and D3 Receptor Occupancy by SIPI6398 | Schizophrenia Disorder | Phase 1/2 | Not yet recruiting | NCT07626034 |
| Oct 2027 | Shenzhen Salubris Pharmaceuticals | GW906A Study to Evaluate Efficacy and Safety of GW906 Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by One or Tw… | Hypertension | Phase 2 | Not yet recruiting | NCT07835984 |
| Oct 2027 | Sirius Therapeutics Co., Ltd. | SRSD384 injectionA Study of SRSD384 in Overweight or Obese Participants | Overweight , Obesity | Phase 1/2 | Not yet recruiting | NCT07557355 |
| Oct 2027 | Spark Therapeutics, Inc. | voretigene neparvovec-rzylPhase 1 Follow-on Study of AAV2-hRPE65v2 Vector in Subjects With Leber Congenital Amaurosis (LCA) 2 | Leber Congenital Amaurosis | Phase 1/2 | Active not recruiting | NCT01208389 |
| Oct 2027 | Spectrum Pharmaceuticals | Eflapegrastim, ChemotherapyA Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated Wi… | Solid Tumors, Lymphoma | Phase 2 | Recruiting | NCT04570423 |
| Oct 2027 | Spyre Therapeutics, Inc. | SPY072, bimekizumabA Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial) | Hidradenitis Suppurativa (HS) | Phase 2 | Recruiting | NCT07766005 |
| Oct 2027 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | ZG005, GecacitinibStudy of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid Tumors | Advanced Solid Tumor | Phase 1/2 | Not yet recruiting | NCT07142837 |
| Oct 2027 | TORL Biotherapeutics, LLC | TORL-1-23, Pegfilgrastim (drug)CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. | Epithelial Ovarian Cancer, Primary Peritoneal and 2 more | Phase 2 | Recruiting | NCT06690775 |
| Oct 2027 | Tarsus Pharmaceuticals, Inc. | TP-05 (lotilaner) Low Dose, TP-05 (lotilaner) High DoseA Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure | Lyme Disease | Phase 2 | Active not recruiting | NCT07562087 |
| Oct 2027 | Toll Biotech Co. Ltd. (Beijing) | TollB-001 TabletA Phase II Study of TollB-001 Tablets in Systemic Sclerosis | Systemic Sclerosis (SSc) | Phase 2 | Not yet recruiting | NCT07745725 |
| Oct 2027 | Transdermal Delivery Solutions Corp | Testosterone, Pump SprayerA Dose Ranging Study to Examine TDS-Testosterone 5% | Hypogonadotropism | Phase 2 | Not yet recruiting | NCT01894308 |
| Oct 2027 | Transdermal Delivery Solutions Corp | Testagen® TDS Testosterone 5% HypoSpray®Product Transference Study of Testagen™ TDS®-Testosterone | Hypogonadotropism | Phase 2 | Not yet recruiting | NCT02733133 |
| Oct 2027 | Upstream Bio, Inc. | VerekitugA Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD | Chronic Obstructive Pulmonary Disease | Phase 2 | Active not recruiting | NCT06981078 |
| Oct 2027 | Veru Inc. | Enobosarm, Semaglutide (Wegovy) weekly injectionProof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist… | Obesity & Overweight, Mobility Disability and 1 more | Phase 2 | Active not recruiting | NCT07446998 |
| Oct 2027 | Vogenx, Inc. | Mizagliflozin 5 mg, Mizagliflozin 10 mgEffect of Mizagliflozin on Hypoglycemia in Patients With Post-Bariatric Hypoglycemia | Postbariatric Hypoglycemia | Phase 2 | Not yet recruiting | NCT07760961 |
| Oct 2027 | Zomagen Biosciences Ltd. | VTX2735An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis | Recurrent Pericarditis | Phase 2 | Recruiting | NCT06836232 |
| Oct 2027 | Argenx SE | Empasiprubart IV, Efgartigimod PH20 SC PFSADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR… | AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis (MG) and 2 more | Phase 2 | Recruiting | NCT07673627 |
| Oct 1, 2027 | AstraZeneca | AZD0120AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1) | Relapsed/Refractory Multiple Myeloma | Phase 1/2 | Recruiting | NCT05850234 |
| Oct 1, 2027 | AstraZeneca | Osimertinib, AmivantamabA Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epider… | Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Active not recruiting | NCT05801029 |
| Oct 1, 2027 | AstraZeneca | Datopotamab deruxtecan (Dato-DXd), Capecitabine, 5-Fluorouracil and 6 moreStudy of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) | Endometrial Cancer, Gastric Cancer and 5 more | Phase 2 | Recruiting | NCT05489211 |
| Oct 1, 2027 | BioAegis Therapeutics Inc. | Rhu-pGSN, normal salineRhu-pGSN for Acute Respiratory Distress Syndrome (ARDS) | Acute Respiratory Distress Syndrome, Infections | Phase 2 | Recruiting | NCT05947955 |
| Oct 1, 2027 | CellSight Technologies, Inc. | [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguan…Imaging Immune Activation in COVID-19 | Covid19, SARS-CoV Infection | Phase 2 | Recruiting | NCT04815096 |
| Oct 1, 2027 | Cho Pharma Inc. | CHO-A04Study of CHO-A04 in Advanced Solid Tumors | Advanced Solid Tumors | Phase 1/2 | Not yet recruiting | NCT07049458 |
| Oct 1, 2027 | NeuroGenesis Ltd. | NG01 - Autologous bone marrow derived human stromal cells, Sodium Chloride 0.9%Study of NG01 Cell Therapy in Secondary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis (SPMS) | Phase 2 | Not yet recruiting | NCT06961383 |
| Oct 1, 2027 | Novartis | DYP688A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas | Metastatic Uveal Melanoma | Phase 1/2 | Active not recruiting | NCT05415072 |
| Oct 1, 2027 | Qingdao WanMing BioCell Pharmaceutics Co.,Ltd. | G01 Eye Drops 100μg/ml, G01 Eye Drops 200μg/mlA Phase II Trial of G01 Eye Drops for Glaucomatous Optic Neuropathy | Primary Open-Angle Glaucoma, Optic Nerve Injury | Phase 2 | Recruiting | NCT07777861 |
| Oct 1, 2027 | SpliSense Ltd. | SPL84Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients With Cystic Fibrosis | Cystic Fibrosis | Phase 2 | Recruiting | NCT06429176 |
| Oct 1, 2027 | Zhejiang Hisun Pharmaceutical Co. Ltd. | AST-3424, Regorafenib TabletsPhase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma | HCC - Hepatocellular Carcinoma | Phase 2 | Recruiting | NCT07310173 |
| Oct 4, 2027 | AstraZeneca | AZD2373-Arm 1, AZD2373-Arm 2, APOL1 Genotyping Clinical Trial AssayDose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease | APOL1-Mediated Kidney Disease | Phase 2 | Active not recruiting | NCT06824987 |
| Oct 4, 2027 | Novo | UBT251, SemaglutideA Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes | Diabetes Mellitus, Type 2 | Phase 2 | Recruiting | NCT07668388 |
| Oct 8, 2027 | Shenzhen Salubris Pharmaceuticals | SAL0140 TabletsA Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Chronic Kidney Disease | Chronic Kidney Disease | Phase 2 | Not yet recruiting | NCT07647133 |
| Oct 8, 2027 | Viatris | cenerimod 4 mgA Study to Evaluate the Safety,Tolerability,Pharmacokinetics and Pharmacodynamics of Cenerimod in Adult Chinese Participants With Moderate-t… | SLE - Systemic Lupus Erythematosus | Phase 2 | Active not recruiting | NCT07266090 |
| Oct 8, 2027 | Xadcera Biopharmaceutical (Suzhou) Co., Ltd. | DM002A Study of DM002 in Patients With Advanced Solid Tumors | Ovarian Neoplasms, Prostatic Neoplasms and 4 more | Phase 1/2 | Recruiting | NCT06751329 |
| Oct 10, 2027 | Suzhou Forlong Biotechnology Co., Ltd | FL115, FL115+BCGA Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer | Non-muscle Invasive Bladder Cancer (NMIBC) | Phase 1/2 | Recruiting | NCT07122414 |
| Oct 11, 2027 | AstraZeneca | TarperprumigSafety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Phase 2 | Recruiting | NCT07160608 |
| Oct 11, 2027 | AstraZeneca | ALXN2030Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation | Antibody-Mediated Rejection, Kidney Transplantation and 2 more | Phase 2 | Active not recruiting | NCT06744647 |
| Oct 12, 2027 | Merck & Co. | MK-7262, EnlicitideA Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004) | Lipoprotein(a) | Phase 2 | Recruiting | NCT07614984 |
| Oct 12, 2027 | Takeda Pharmaceutical Company | ZasocitinibA Study of Zasocitinib in Adults With Nonsegmental Vitiligo | Nonsegmental Vitiligo | Phase 2 | Recruiting | NCT07108283 |
| Oct 13, 2027 | Sanofi | SAR446597, Sham ComparatorA Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-relat… | Geographic Atrophy | Phase 1/2 | Recruiting | NCT07215234 |
| Oct 14, 2027 | Intra-Cellular Therapies, Inc. | ITI-1284 10 mg, ITI-1284 20 mgStudy of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder | Generalized Anxiety Disorder | Phase 2 | Recruiting | NCT06701903 |
| Oct 15, 2027 | Haisco Pharmaceutical Group Co., Ltd. | HSK47388A Study for HSK47388 in Participants With Ulcerative Colitis | Ulcerative Colitis (UC) | Phase 2 | Recruiting | NCT07335055 |
| Oct 15, 2027 | ImCheck Therapeutics, an Ipsen company | IV ICT01First-in-Human Study of ICT01 in Patients With Advanced Cancer | Solid Tumor, Adult, Hematopoietic/Lymphoid Cancer | Phase 1/2 | Active not recruiting | NCT04243499 |
| Oct 15, 2027 | Vector Y Therapeutics | VTx-002, Preventative (Prophylactic) Medication - Corticosteroids: …Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS | Amyotrophic Lateral Sclerosis | Phase 1/2 | Recruiting | NCT07287397 |
| Oct 18, 2027 | Bausch Health | plecanatideThis is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Efficacy and Safety of 2 Weight-based Treat… | Functional Constipation (FC) | Phase 2 | Recruiting | NCT07723924 |
| Oct 18, 2027 | Pfizer | PF-08634404, IpilimumabSymbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participa… | Carcinoma, Hepatocellular, Hepatocellular Cancer and 5 more | Phase 1/2 | Recruiting | NCT07227012 |
| Oct 19, 2027 | Cellcolabs Clinical LTD. | Human Allogeneic Bone-Marrow (BM) -Derived Mesenchymal Str…A Study of Human Allogeneic Bone-marrow Derived Mesenchymal Stromal Cell Product (StromaForte) in Patients With Musculoskeletal Injuries and… | Musculoskeletal Injury | Phase 1/2 | Recruiting | NCT06074783 |
| Oct 19, 2027 | Novartis | CTL019Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients | B-Cell Acute Lymphoblastic Leukemia | Phase 2 | Active not recruiting | NCT03876769 |
| Oct 20, 2027 | Chendu DIAO Pharmaceutical Group CO., LTD. | DA-302168SA Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Subjects With Type 2 Diabetes | Type 2 Diabetes Mellitus | Phase 2 | Not yet recruiting | NCT07755150 |
| Oct 20, 2027 | Jiangsu Aosaikang Pharmaceutical Co., Ltd. | ASK0912 for Injection, Polymyxin B Sulfate for InjectionASK0912 Versus Polymyxin B for Injection in Adults With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia | Ventilator-associated Bacterial Pneumonia (VABP), Hospital-acquired Bacterial Pneumonia (HABP) | Phase 2 | Recruiting | NCT07759934 |
Trials: ClinicalTrials.gov, the U.S. National Library of Medicine’s registry, industry-sponsored studies only. Completion dates are the sponsor’s own estimates and often slip. Advisory committees: the FDA advisory committee calendar. A trial’s primary completion is when its main measurement is done; companies usually report top-line results weeks to months later, and not always. FDA decision dates (PDUFA goal dates) are not here: the FDA does not publish them, and companies announce them only in their own press releases.